

**SUPPLEMENTARY MATERIALS TO:  
SYNTHESIS, CRYSTAL STRUCTURE, AND DFT STUDY  
OF 4-(2-CHLOROBENZYL)-1-(5-NITRO-2-(PYRROLIDIN-1-YL)PHENYL)-  
[1,2,4]TRIAZOLO[4,3-a]QUINAZOLIN-5(4H)-ONE**

**Q. Ren<sup>1,2</sup>, P.-Y. Huang<sup>2,3</sup>, Y. Liu<sup>1,2</sup>, W.-K. Liao<sup>4</sup>, Z.-X. Zhou<sup>1,2,5</sup>, C.-S. Zhao<sup>1,2</sup>**

<sup>1</sup>*School of Pharmaceutical Sciences, Guizhou University, Guiyang, People's Republic of China*

E-mail: 1799144072@qq.com, zhixuzhou@126.com, chunshenzhao@163.com

<sup>2</sup>*Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, People's Republic of China*

<sup>3</sup>*Chemistry and Chemical Engineering, Guizhou University, Guiyang, People's Republic of China*

<sup>4</sup>*Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, People's Republic of China*

<sup>5</sup>*Department of Dermatology, Affiliated Hospital of Guizhou Medical University, Guiyang, People's Republic of China*




Fig. S1. <sup>1</sup>H-NMR spectrum of 1.




Fig. S2.  $^{13}\text{C}$ -NMR spectrum of **1**.

05 #33 RT: 0.33 AV: 1 NL: 5.78E7  
T: FTMS +p ESI Full ms [100.0000-1000.0000]




Fig. S3. MS spectrum of **1**.




Fig. S4. IR spectrum of 1.